Generic Price-Fixing Lawsuit Grows As More Companies, Two Executives Named Defendants
US state attorneys general name executives from Mylan and Emcure as defendants, and list may further expand as investigation continues into additional companies and drugs.
You may also be interested in...
As state attorneys general and Department of Justice move against generic manufacturers, plaintiffs’ firms have filed more than 90 antitrust suits on behalf of third party payers.
Heritage Pharmaceuticals’ former CEO and former president charged by US DOJ with conspiracy to fix prices and allocate customers for doxycycline and glyburide; Heritage alleges they embezzled intellectual property.
The goal of the Office of New Drugs’ initiative is to develop and execute, in a cross-disciplinary manner, strategic plans to address substantive development hurdles in specific therapeutic areas. This approach already has been used for non-healing, chronic wounds and is being expanded to neurodegenerative and rare diseases, OND’s Peter Stein tells the Pink Sheet.